Table 1. Baseline characteristics of patients enrolled in the effective and placebo/ineffective treatment groups.
| Effective treatment (n = 139) | Placebo/ineffective treatment (n = 28) | p-value | |
| Female, n (%) | 106 (76.3) | 18 (64.3) | 0.186 |
| Age (years) | 55 (47–63) | 51 (36–59) | 0.097 |
| EULAR responder, n (%) | 110 (79.1) | 10 (35.7) | <0.0001 |
| TJC68 | 10 (6–17) | 10 (4–12) | 0.093 |
| SJC68 | 7 (4–12) | 8 (6–11) | 0.633 |
| ESR | 22 (12–37) | 28 (18–56) | 0.122 |
| CRP | 9 (3.5–22) | 13 (6–47) | 0.029 |
| DAS28-CRP | 4.72 (4.05–5.87) | 4.77 (4.41–5.46) | 0.662 |
Median and interquartile range or percentages are shown. EULAR responder = good or moderate responder according to the European League Against Rheumatism Response, TJC68 = tender joint count of 68 joints, SJC68 = swollen joint count of 68 joints, ESR = erythrocyte sedimentation rate, CRP = C-reactive protein, DAS28-CRP = disease activity score based on CRP. P-value <0.05 was considered statistically significant. Significance of the comparison is determined by the chi-square test or the Mann-Whitney test.